VERV
Companies
NASDAQ
Verve Therapeutics Inc.
Health Care
$11.17
+$5.53 (+98.05%)
Price Chart
Overview
About VERV
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Market Cap
$437.5M
Volume
31.9M
Avg. Volume
53.0M
P/E Ratio
-1.5951557
Dividend Yield
0.00%
Employees
243.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.39
High Correlation
Volatility
High (0.92)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, VERV shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$437.5M
Volume31.9M
P/E Ratio-1.60
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2024Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025